Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mifomelatide in Newly Diagnosed CRC or PDAC Undergoing Chemotherapy
NCT06937177Phase 2Recruiting
- Sponsor
- Endevica Bio
- Start
- Apr 2025
- Primary completion
- Oct 2027
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of mifomelatide in cancer (4 arms), sponsored by Endevica Bio. Primary endpoints: Change from baseline in body weight at 12 weeks, Incidence and severity of adverse events (AEs), AESIs, and SAEs at 12 weeks and 2 more. Started Apr 2025; status: recruiting.
02
Drugs
mifomelatide
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06937177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06937177.